SNOA beat EPS expectations by 10.49%
Feb 13, 2025, 11:33 PM
0.00%
What does SNOA do
Sonoma Pharmaceuticals, headquartered in Boulder, Colorado, develops hypochlorous acid products for various healthcare applications and went public on January 26, 2007. Their product lineup includes Lumacyn, Regenacyn, and MicrocynAH for skin and wound care.
Sonoma Pharmaceuticals (SNOA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Sonoma Pharmaceuticals's actual EPS was -$0.63, beating the estimate of -$0.70 per share, resulting in a 10.49% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.